CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Reshma Kewalramani

Chief Executive Officer, President & Director, Vertex Pharmaceuticals

Search every verified Reshma Kewalramani interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Reshma Kewalramani, CEO of Vertex Pharmaceuticals, commented on the FDA’s approval of Casgevy, a gene-editing treatment for sickle cell disease based on CRISPR/Cas9 technology. She described the approval as a historic day for patients and said the medicine holds the promise of being a one-time curative treatment. Kewalramani stated that patients have described the pain of sickle cell disease as worse than childbirth and that they would characterize the treatment as a cure. She noted that the treatment has a wholesale price of $2.2 million and said Vertex believes the price reflects the value of a one-time therapy that could provide a lifetime of cure. Kewalramani said Vertex has engaged with patients, physicians, and payers, including both private and government entities, and reported unanimous enthusiasm for the treatment. She added that sickle cell disease has been marginalized and that there has been a lack of innovation in the field for many years. She explained that the process involves taking a patient’s own stem cells, editing them in a lab, and returning them to the patient to offer the opportunity to live a life free from pain crises.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →